Biogen's $5.6B Bet on Your Grandparents' Eyes

As of late 2025, Apellis reported holding roughly 60% of the GA market. But Izervay has benefited from safety concerns around Syfovre, particularly worries about retinal vasculitis (inflammation of blood vessels in the eye). Physicians who prioritize safety over broader efficacy have sometimes leaned toward the competitor.

The good news for Biogen: this is still basically a two-drug market. Multiple analysts expect no immediate pipeline threats through 2026, though oral therapies and next-generation complement inhibitors are lurking in later-stage development.

Why Biogen Needs This Deal

Biogen has a problem that's familiar to anyone who's ever relied too much on one thing. For years, the company lived and died by neuroscience, particularly its multiple sclerosis franchise. But MS drug revenues have been declining, and its newer launches (Leqembi for Alzheimer's, Skyclarys for rare disease, Zurzuvae for postpartum depression) haven't fully filled the gap.

The company's playbook since 2023 has been selective diversification. It acquired Reata Pharmaceuticals to get Skyclarys. It bought HI-Bio in 2024 to add felzartamab, an immunology asset now in Phase 3 for kidney diseases. And now Apellis, which brings both an ophthalmology product and something perhaps even more strategically important: a commercial infrastructure in nephrology.

That nephrology angle is sneaky smart. Apellis also sells Empaveli, a complement inhibitor for rare blood and kidney diseases. Together, Empaveli and Syfovre generated $689 million in combined 2025 net product revenue. Biogen gets immediate revenue and a launchpad for felzartamab's eventual kidney disease commercialization. Two birds, one $5.6 billion stone.

The Math Behind the CVRs

The contingent value rights are where this deal gets interesting. They're essentially a bet between Biogen and Apellis shareholders on Syfovre's future.

If Syfovre hits $1.5 billion in annual global net sales in any year from 2027 to 2030, shareholders get an extra $2 per share. If it reaches $2 billion in that same window, they get another $2 per share on top of that. There's even a safety net: if neither milestone triggers by 2030, shareholders can still collect the full $4 per share if sales hit $2 billion in 2031.

Getting from roughly $590 million to $1.5 billion is more than a gentle climb; it's a near-tripling. Biogen said the deal should be accretive to earnings per share by 2027 and boost its EPS growth rate through the end of the decade. Some analysts, including those at William Blair, projected the acquired assets could generate $1.54 billion in sales by 2030. If that's right, the first CVR tranche would trigger, and the deal starts looking like a bargain.

If it's wrong, Biogen still got two marketed drugs and a kidney disease commercial platform for $41 a share. Not exactly a disaster.

Wall Street's Verdict: Cautiously Optimistic

Analysts have largely called the deal a solid strategic fit, according to Reuters. The logic is straightforward: Biogen needs revenue now, and Apellis has revenue now. The kidney disease infrastructure is a bonus that could pay dividends when felzartamab is ready for prime time.

But there's skepticism, too. Some analysts questioned the premium, especially given Syfovre's softening revenue trend. Paying above consensus price targets for a drug whose sales declined year-over-year requires a leap of faith that Biogen's commercial muscle can reignite growth.

Perhaps tellingly, post-acquisition reports indicate Biogen has scaled back most of Apellis' research programs, keeping the focus on commercial assets rather than the broader R&D portfolio. This wasn't a bet on Apellis' science. It was a bet on Apellis' products.

The Bigger Picture

Biogen is doing something that a lot of legacy pharma companies are attempting right now: reinventing itself without blowing up what already works. Neuroscience remains the core. But the company is layering on immunology, rare disease, and now ophthalmology like a contractor adding rooms to a house. Each acquisition extends the footprint without requiring a complete rebuild.

The Apellis deal is the most expensive room yet. Whether it's a master suite or a money pit depends on one question: can Biogen do for Syfovre what Apellis couldn't quite manage on its own? If the answer is yes, the CVRs pay out, the revenue gap closes, and Biogen's diversification story writes itself.

If not, well, at least they've got a nice kidney disease platform to fall back on.

The Flu Shot Just Got Its Biggest Upgrade in Decades

The FDA just approved the first-ever mRNA flu vaccine, and it beat traditional shots in a 41,000-person trial. Moderna's mFlusiva won't make much money this year, but it might reshape a $9 billion market.